TIL Therapy in cSCC and MCC (NCT07288073)
A Feasibility Study of Tumor Infiltrating Lymphocytes in Cutaneous Squamous Cell Carcinoma and Merkel Cell Carcinoma
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this research study is to test the safety and effectiveness of a tumor-infiltrating lymphocyte (TIL) cellular therapy, also called LN-145 or lifileucel, and chemotherapy in combination with Interleukin-2 (IL-2) to find out what effects, if any, the combination has on participants with Cutaneous squamous cell carcinoma (CSCC) or Merkel Cell Carcinoma (MCC) who were previously treated with immunotherapy. The names of the study interventions involved in this study are: * Tumor Infiltrating Lymphocytes (a type of cellular therapy) * Fludarabine and Cyclophosphamide (types of standard of care chemotherapy drugs) * Interleukin-2 (a type of recombinant, human glycoprotein)
Who can join: Review the eligibility criteria below.
Location: Dana-Farber Cancer Institute — Boston, Massachusetts
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- Dana-Farber Cancer Institute — Boston, Massachusetts
📞 Contact the Study Coordinator
Phone: (617) 632-6571
Email: karam_khaddour@dfci.harvard.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Cutaneous Squamous Cell Carcinoma
- Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer — La Jolla, California
- A Study to Evaluate INCB099280 in Participants With Advanced Cutaneous Squamous Cell Carcinoma — Albury, New South Wales
- A Study of Radiation Therapy and Cemiplimab for People With Skin Cancer — Aurora, Colorado
- Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma — Gilbert, Arizona
- Phase 2 Study of Ivonescimab in Patients With Cutaneous Squamous Cell Carcinoma — Houston, Texas
- Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy — Boston, Massachusetts
Explore by condition: All Cutaneous Squamous Cell Carcinoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.